3-溴-5-硝基三氟甲苯 | 630125-49-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-5-硝基三氟甲苯
• 中文别名: 3-硝基-5-溴三氟甲苯；3-三氟甲基-5-溴硝基苯
• 英文名称: 1-bromo-3-nitro-5-(trifluoromethyl)benzene
• 英文别名: 3-bromo-5-nitrotrifluorotoluene；3-bromo-5-nitrobenzotrifluoride
• CAS: 630125-49-4
• 化学式: C₇H₃BrF₃NO₂
• 分子量: 270.006
• InChiKey: YHTVYRKVFAFVLP-UHFFFAOYSA-N

物化性质

• 沸点：
  223.7±35.0 °C(Predicted)
• 密度：
  1.788±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2904909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H227,H302,H315,H319,H332,H335
• 储存条件：
  按规定使用和贮存时不会分解，并应避免接触氧化物。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-3-nitro-5-trifluoromethylbenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H312: Harmful in contact with skin
H332: Harmful if inhaled
H315: Causes skin irritation
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P337+P313: If eye irritation persists get medical advice/attention

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-3-nitro-5-trifluoromethylbenzene
CAS number: 630125-49-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H3BrF3NO2
Molecular weight: 270.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：黄色液体

反应信息

• 作为反应物：
  描述：

  3-溴-5-硝基三氟甲苯 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以86%的产率得到3-氨基-5-溴三氟甲苯
  参考文献：
  名称：

  工业杉木碳负载 FeO(OH) 纳米粒子催化硝基芳烃加氢

  摘要：

  开发绿色、高效的硝基芳烃加氢方法在有机合成中仍然具有很高的要求。在此，我们报告了一种工业杉木碳负载的 FeO(OH) 纳米颗粒工艺，该工艺用于通过硝基芳烃的氢化以良好的产率合成芳胺。九个关键的抗癌药物中间体通过协议成功实现。并且 Osimertinib 中间体4 m可以在 2.67 kg 的规模下顺利合成，HPLC 纯度 >99.5%。该协议具有碳源廉价、催化活性高、操作简单、催化剂公斤级可回收（八次无明显损失活性）等特点。

  DOI：

  10.1016/j.catcom.2022.106398
• 作为产物：
  描述：

  三氟甲苯 在 硫酸 、 溴 、 硝酸 作用下， 反应 6.0h， 生成 3-溴-5-硝基三氟甲苯
  参考文献：
  名称：

  一种用于C–X偶联的高效基于d-氨基葡萄糖的铜催化剂及其在尼罗替尼中间体的合成中的应用†

  摘要：

  已经通过氮和硫亲核试剂与芳基碘化物和溴化物的交叉偶联反应研究了D-氨基葡萄糖的C–N和C–S键的形成。咪唑，苯并咪唑，吲哚，吡咯烷和二苯基二硫化物在10摩尔％D-葡萄糖胺，10摩尔％CuI和2当量的存在下与芳基卤化物发生反应。DMSO–H 2中的Cs 2 CO 3浓度在中等温度下O可得到相应的产物，收率良好至极佳。具有卤化物，游离氨基，三氟甲基和杂环的底物具有良好的耐受性。配体的高水溶性使其易于去除催化剂。此外，使用市售底物也成功证明了该催化体系在尼罗替尼中间体合成中的应用。

  DOI：

  10.1039/c4ra11183d

文献信息

• [EN] PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRIDINE UTILISÉS COMME INHIBITEURS DE LA KINASE RÉARRANGÉE AU COURS DE LA TRANSFECTION (RET)
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2014141187A1

  公开（公告）日：2014-09-18

  This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

  这项发明涉及一种新型化合物，它们是重排基因转位（RET）激酶的抑制剂，包括含有它们的药物组合物，它们的制备方法，以及它们在治疗中的使用，单独或结合使用，用于规范胃肠敏感性、蠕动和/或分泌以及/或腹部紊乱或疾病的治疗，或与与RET功能障碍相关的疾病相关的治疗，或者调节RET活性可能具有治疗益处的治疗，包括但不限于所有分类的肠易激综合征（IBS），包括以腹泻为主、以便秘为主或交替排便模式、功能性腹胀、功能性便秘、功能性腹泻、未特指的功能性肠道障碍、功能性腹痛综合征、慢性特发性便秘、功能性食管障碍、功能性胃十二指肠障碍、功能性肛门疼痛、炎症性肠病、非小细胞肺癌、肝细胞癌、结肠癌、髓样甲状腺癌、滤泡性甲状腺癌、间变性甲状腺癌、乳头状甲状腺癌、脑肿瘤、腹腔癌、实体肿瘤、其他肺癌、头颈癌、神经胶质瘤、神经母细胞瘤、冯·希普-林道综合征和肾肿瘤、乳腺癌、输卵管癌、卵巢癌、移行细胞癌、前列腺癌、食管和胃食管交界处癌症、胆道癌、腺癌，以及任何具有增加RET激酶活性的恶性肿瘤。
• <i>meta</i> ‐Nitration of Arenes Bearing <i>ortho</i> / <i>para</i> Directing Group(s) Using C−H Borylation
  作者：Xuejing Li、Xingwang Deng、Anthony G. Coyne、Rajavel Srinivasan

  DOI：10.1002/chem.201901633

  日期：2019.6.18

  of arenes bearing ortho/para directing group(s) using the iridium‐catalyzed C−H borylation reaction followed by a newly developed copper(II)‐catalyzed transformation of the crude aryl pinacol boronate esters into the corresponding nitroarenes in a one‐pot fashion. This protocol allows the synthesis of meta‐nitrated arenes that are tedious to prepare or require multistep synthesis using the existing

  在本文中，我们报道了荟萃芳烃的-nitration轴承邻/对位用铱催化的C-H硼化反应之后是新开发的铜（II）粗频哪醇的芳基硼酸酯入的催化的变换引导组（多个）以一锅的方式对应的硝基芳烃。该协议允许的合成元-nitrated芳烃是乏味来制备或使用现有的方法需要多步合成。该反应可耐受多种邻位/对位导向基团，例如-F，-Cl，-Br，-CH 3，-Et，-i Pr -OCH 3和-OCF 3。它还提供对π电子缺陷杂环的硝基衍生物（例如吡啶和喹啉衍生物）的区域选择性访问。该方法的应用在复杂分子的后期修饰中以及在以克级制备到FDA批准的药物Nilotinib途中的中间体中得到了证明。最后，我们证明了通过该策略获得的硝基产物也可以通过Baran的胺化方案直接转化为苯胺或受阻胺。
• [EN] PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS<br/>[FR] DÉRIVÉS DE LA PHTALAZINE COMME INHIBITEURS DE JAK1
  申请人：EXELIXIS INC

  公开号：WO2012037132A1

  公开（公告）日：2012-03-22

  JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  JAK1抑制剂的结构公式(I)，其中Ar1、Ar2、Q、W、X、Y和Z在说明书中定义，药用可接受的盐，它们的组合物以及用于治疗疾病的化合物和组合物的用途。本发明还包括在制造药物中的用途，特别是在治疗疾病中的用途。
• [EN] NOVEL INHIBITORS OF MAP4K1<br/>[FR] NOUVEAUX INHIBITEURS DE MAP4K1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2018215668A1

  公开（公告）日：2018-11-29

  The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

  本发明涉及新的MAP4K1（HPK1）抑制剂，用于治疗由与MAPK激活相关的信号转导途径失调引起的疾病或病症，包括过度增殖性疾病、免疫系统功能障碍性疾病、炎症性疾病、神经系统疾病和心血管疾病。本发明进一步涉及包含相同抑制剂的药物组合物以及治疗所述疾病和病症的方法。所述抑制剂的结构式为(I)，其中A、D、E、F、R5、R6、R7、Z、环Q、n、x和y的定义如申请中所述。
• [EN] NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS<br/>[FR] NOUVELLES QUINAZOLINES À SUBSTITUTION BENZYLAMINO ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS DE SOS1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018115380A1

  公开（公告）日：2018-06-28

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）的化合物，其中基团R1至R7具有权利要求和说明中给定的含义，它们作为SOS1的抑制剂的用途，包含这种化合物的药物组合物以及它们作为药物/医疗用途的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。